For decades, the go-to treatments for cancer have been chemotherapy, radiation and surgery — but some experts are calling ...

Tina Willits, now 53, thought she had just two years to live. Today, she is cancer-free — and she wants the world to know ...

As the founder and CEO of Immunocine Cancer Center, based in Cancún, Mexico, he has transformed his vision into reality with ...

Dan G. Duda, DMD, Ph.D., of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at ...

AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...

Candel Therapeutics, Inc. (NASDAQ:CADL) announced results from a phase 3 trial of CAN-2409 viral immunotherapy in ...

Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General ... How would you summarize your study for a lay audience? Immunotherapy has revolutionized the ...

CAN-2409 resulted in disease-free survival improvements for patients with high-risk, localized prostate cancer.

Checkpoint Therapeutics’ stock has seen a remarkable +60.26% year-to-date increase, far surpassing the S&P 500’s YTD performance of +26.86%. This highlights how well Checkpoint is positioning itself ...

Candel’s trial was conducted under the FDA’s Special Protocol Assessment program, meaning that its data could be used as a ...

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in ...